Hesham Abdelrazek, MD
Pulmonary Disease · Phoenix, AZNPI 1841266681
Payments from drug & device makers
Across 47 payments — averaging $36.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragonix Technologies, Inc.$266
- Actelion Pharmaceuticals US, Inc.$237
- Astellas Pharma US Inc$199
- AbbVie$189
- Takeda Pharmaceuticals U.S.A., Inc.$132
- Merck$113
- plus $602 from 15 others
What the payments were for
- Food & beverage$1,56090%
- Education$17810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragonix Technologies, Inc. | 2 | $266 |
| Actelion Pharmaceuticals US, Inc. | 6 | $237 |
| Astellas Pharma US Inc | 3 | $199 |
| AbbVie | 7 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $132 |
| Merck | 5 | $113 |
| Intuitive Surgical | 1 | $90 |
| Pulmonx Corporation | 1 | $84 |
| Boehringer Ingelheim | 4 | $73 |
| Insmed, Inc. | 3 | $72 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Biomerieux Inc | 1 | $33 |
| Eurofins Viracor, LLC | 1 | $32 |
| Sanofi | 2 | $29 |
| Vifor Pharma, Inc. | 1 | $24 |
| Atricure, Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $22 |
| Invivyd Inc | 1 | $21 |
| Verona Pharma, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $21 |
| AstraZeneca | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUNGguard$266
- BaroGuard$266
- LIVTENCITY$102
How this compares
$1,738 in reported general payments places this provider in the 40th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrevymisLetermovir | 100 | $772,510 |
| CresembaIsavuconazonium Sulfate | 39 | $431,790 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 31 | $151,442 |
| Posaconazole | 117 | $132,233 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 34 | $110,198 |
| EliquisApixaban | 115 | $105,829 |
| Valganciclovir Hcl | 143 | $95,572 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $90,528 |
| Itraconazole | 146 | $83,499 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $82,496 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 19 | $45,794 |
| Atovaquone | 46 | $29,133 |
| Tacrolimus | 82 | $10,211 |
| Mycophenolate Mofetil | 39 | $6,272 |
| Azithromycin | 187 | $4,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckPrevymis | $113 | $772,510100 claims |
| Astellas Pharma US IncCresemba | $199 | $431,79039 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $132 | $110,19834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Mark GotfriedPhoenix$1.1M
- Abid KhokarPhoenix$321K
- Brian PorvinPhoenix$276K
- Tony HodgesPhoenix$262K
- Rajeev SaggarPhoenix$219K
- Ali SaeedPhoenix$213K
- Bhuvin BuddhdevPhoenix$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.